Should systemic antibiotics be initiated for an 82-year-old woman with chronic bilateral arterial lower-extremity wounds and severe peripheral vascular disease, whose wound culture grew >100,000 CFU/mL Serratia marcescens (susceptible to cefepime, ceftazidime, piperacillin‑tazobactam, gentamicin, and tobramycin), has a normal white blood cell count, and ongoing wound drainage, or should management consist of wound care and clinical monitoring, and is cefepime an appropriate antibiotic if treatment is indicated?

Systemic Antibiotics Are Indicated for This Patient

Given the presence of ongoing wound drainage with >100,000 CFU/mL Serratia marcescens in a patient with severe PVD and chronic limb-threatening ischemia (CLTI), systemic antibiotics should be initiated, and cefepime is an appropriate choice.

Rationale for Treatment

The 2024 ESC guidelines explicitly state that "it is recommended to treat infection with antibiotics" in patients with CLTI 1. While your patient lacks systemic inflammatory signs (normal WBC, presumably afebrile), the combination of:

• High bacterial burden (>100,000 CFU/mL)
• Ongoing purulent drainage
• Severe underlying PVD compromising tissue perfusion
• Advanced age (82 years) with limited physiologic reserve

creates substantial risk for progression to deeper infection, osteomyelitis, or systemic sepsis that could result in limb loss or mortality 1.

Why the Normal WBC Doesn't Change Management

The IDSA guidelines acknowledge that absence of leukocytosis does not exclude clinically significant infection in wound contexts 2. The guidelines focus on local wound signs (drainage, erythema) rather than requiring systemic inflammatory markers for treatment decisions. In elderly patients with PVD, blunted inflammatory responses are common, and waiting for systemic signs risks irreversible tissue loss 1.

Critical distinction: The IDSA criteria stating antibiotics are "unnecessary" when WBC <12,000 cells/µL apply specifically to surgical site infections with <5 cm erythema and minimal systemic signs 2. Your patient has a chronic arterial wound with active drainage and severe PVD—a fundamentally different clinical scenario requiring lower threshold for treatment.

Cefepime Is Appropriate

Cefepime is an excellent choice for this Serratia marcescens infection:

• Documented susceptibility on culture
• Fourth-generation cephalosporin with excellent gram-negative coverage including Serratia
• Lower risk of AmpC β-lactamase induction compared to third-generation cephalosporins 3
• Appropriate for moderate-to-severe infections in elderly patients with renal dosing adjustments 4

Dosing consideration: Given her age, verify renal function and adjust cefepime dose accordingly (standard 1-2g IV q8-12h if CrCl >40 mL/min; reduce frequency if lower) 4.

Alternative Considerations

While piperacillin-tazobactam is also susceptible and commonly used for wound infections 2, 4, cefepime offers:

• Narrower spectrum (better stewardship for documented Serratia)
• Less sodium load (important in elderly with potential cardiac issues) 4
• Equivalent efficacy for this pathogen

Aminoglycosides (gentamicin/tobramycin) should be avoided as monotherapy given nephrotoxicity risk in an 82-year-old, though could be considered for 3-5 days as combination therapy if severe infection develops.

Treatment Duration and Monitoring

• Initial course: 7-14 days depending on clinical response
• Monitor: Wound drainage reduction, surrounding erythema, pain improvement
• Red flags requiring escalation: Fever >38.5°C, expanding erythema >5 cm, systemic signs, crepitus suggesting necrotizing infection 2
• If deep infection suspected: Obtain imaging (X-ray/MRI) to rule out osteomyelitis, which would require 4-6 weeks of therapy 1

Essential Concurrent Management

Antibiotics alone are insufficient. The 2024 ESC guidelines emphasize vascular team involvement and aggressive wound care 1:

• Offloading: Mandatory to allow healing 1
• Wound debridement: Remove necrotic tissue to reduce bacterial burden
• Vascular assessment: Consider revascularization if not already optimized—healing is unlikely without adequate perfusion 1
• Specialized dressings: Antimicrobial or negative pressure therapy may accelerate healing 1

Common Pitfall to Avoid

Do not wait for systemic signs (fever, leukocytosis, sepsis) to initiate antibiotics in CLTI patients with documented high bacterial burden and drainage. By the time systemic signs appear in this population, tissue damage may be irreversible and amputation risk substantially elevated 1, 5. The goal is limb salvage, which requires aggressive early intervention.

The evidence consistently shows that patients with CLTI and infected wounds have 3.9-fold increased risk of bloodstream infection compared to non-CLTI PAD patients 5, and infection is a major driver of 30-day readmissions post-intervention 5. Early systemic antibiotics combined with optimal wound care and vascular optimization offers the best chance of preserving this patient's remaining limb 1, 6.